Drug safety
The world's first liquid pathology platform for drug safety, LiquiPath™
A new gold standard powered by blood-based, multi-organ monitoring.
LiquiPath
The first liquid biopsy for drug safety monitoring
From a single blood sample, LiquiPath traces cell-free DNA (cfDNA) back to its tissue of origin, monitoring for signs of injury across multiple organs and enabling accurate detection of safety signals.
Non-human
Preclinical drug safety monitoring
- Multi-organ monitoring without pathology
- Faster readout and decisions
- Streamlined preclinical safety studies
- Mechanistic insights
- Identify causes of tolerability issues missed in safety studies
Early access programme now open
Human
Clinical drug safety monitoring
- Early detection of tissue damage
- Multi-organ readout from a single sample
- Safety signals where blood-based biomarkers are lacking
- Non-invasive, repeatable monitoring
- Rapid turnaround times
- Stratification of safety signals by type and grade
Early access programme now open
Join the revolution
Early access customers will have the opportunity to shape the capabilities of our organ health platform before general availability
Contact us to learn more about how we can improve your safety monitoring approach
Contact usLiquiPath
Our novel approach to drug safety
Using our LiquiPath platform, we turn a single blood sample into real-time insight across multiple organs simultaneously, giving drug developers the clarity to create safer therapies faster.
Biomarker enrichment with Activace™
With our cutting-edge enrichment technology, we selectively isolate the most cell- and tissue-specific epigenetic markers from a single blood sample.
Cell-type-specific signal quantification
Tagomics has created the world’s first commercial, multi-species, cell-type-specific methylation atlases, developed by profiling sorted cells with Activace. Our bespoke statistical models use these atlases to trace plasma cfDNA fragments back to their tissue of origin, enabling precise quantification of injury.
Precision drug safety insights
By monitoring changes in DNA originating from each tissue, we provide highly sensitive and specific insights into treatment response, adverse events, and organ health in preclinical and clinical studies.
Other applications
The future of organ health
Our platform offers new opportunities to understand and monitor organ health across a range of clinical and research settings, with future applications in treatment efficacy, chronic disease and transplant rejection.
Tagomics introduces LiquiPath, a first-in-class cfDNA-based blood test for multi-organ drug safety monitoring
Non-invasive cell-free DNA liquid biopsy platform for multi-organ monitoring of drug-safety across preclinical and clinical settings
Early access programme now open for drug developers to shape future platform capabilities and applications
New brand identity and website mark the expansion of Tagomics’ product portfolio into organ health monitoring
Press releases
The Scientist | Innovation Spotlight: unlocking better diagnostics through multiomic biomarkers
Robert Neely from Tagomics shares how simultaneous genomic and epigenomic profiling can drive more precise and timely healthcare.
Press releases
Drug Discovery News: could we diagnose cancer earlier than ever before?
Methylation profiling of cell-free DNA is opening new possibilities for detecting cancer at its earliest, pre-symptomatic stages, offering a potential breakthrough in how and when disease is found.
Press releases
Technology Networks: academic origins driving impact in epigenetic diagnostics
Non-destructive analysis offers simultaneous genomic, epigenomic and fragmentomic information from a single sample. Karen Steward, PhD speaking with Rob Neely, PhD & Mark Garner, PhD.
Press releases
Medlespod podcast with CSO Rob Neely
Tagomics Wins NHS Grant, Unveils De-Methylation Platform for Early Cancer Testing with Rob Neely, CSO
Press releases
Tagomics Seeks Unmethylated Genomic Regions as Part of Data Package for Drug Development
Tagomics, a UK-based startup, has recently emerged from stealth with a new way to look at methylation, or lack thereof, in the human genome.
Press releases
Tagomics awarded £860k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer
- Grant forms part of £1.2M project to customise Tagomics’ multiomic profiling platform for early detection of colorectal cancer.
- Early detection test to be developed in collaboration with the Salford Royal NHS Foundation Trust and the Northern Care Alliance Research Collection biobank.
Press releases
Calculus leads £6.7m funding round into Tagomics
Tagomics, developers of a cutting-edge platform for comprehensive disease insight and diagnosis, today announces a £6.7m funding round. This achievement follows a £1.6m pre-seed round led by IQ Capital and Start Codon and including grant funding from Innovate UK.
Scientific publications
JCO Precision Oncology: Cell-Free DNA to Detect and Monitor Toxicity Signals
Tagomics’ Organ Health Programme Lead Dr John Gallon, Scientific Advisory Board member Professor Yuval Dor, and our partners at AstraZeneca have co-authored a paper recently published in JCO Precision Oncology exploring the next frontier in cfDNA applications: precision drug safety monitoring.
Scientific publications
Tagomics publishes a new approach to genome-wide epigenomic profiling
- Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsy
- Activace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive view of the epigenome that can be scaled to the study of large patient cohorts